secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001048477-24-000082
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin to cut ~170 jobs, book $15-20M charge from R&D program exits
---------------------------------------------------------------------

- Strategic portfolio assessment led to discontinuation of certain R&D programs.
- Workforce reduction of approximately 170 employees; majority notified May 14, 2024.
- Estimated $15-20M pre-tax charges in Q2 2024 for severance and termination benefits.
- Workforce reductions expected to be substantially completed by end of July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000082/0001048477-24-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000082/bmrn-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001048477-24-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer